Ankylosing Spondylitis

Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease that primarily affects the sacroiliac joints and spine, although hips, shoulders, peripheral joints, eyes, skin, and bowel may also be involved. Symptoms commonly begin before age 45 and include inflammatory back pain, morning stiffness, and reduced spinal mobility. Diagnosis is clinical and supported by imaging, laboratory testing, and assessment against established classification frameworks; no single test confirms the condition in every patient.

Care is shifting from symptom control alone toward earlier recognition, sustained disease control, and preservation of function. MRI can help identify active inflammation before structural changes are visible on plain radiographs, while longitudinal assessment increasingly combines pain, stiffness, mobility, extra-musculoskeletal manifestations, quality of life, and treatment safety. Non-pharmacological management-including exercise, posture training, physical therapy, smoking cessation, and patient education-remains foundational alongside pharmacological treatment.

Artificial intelligence may improve AS care by assisting radiographic and MRI interpretation, identifying inflammatory patterns in clinical records, supporting referral prioritization, and enabling remote monitoring of mobility and symptoms. Its practical value depends on representative training data, external validation, explainability, interoperability, and safeguards against unequal performance across populations. At present, AI should be treated as a decision-support capability requiring rheumatologist oversight rather than as a substitute for clinical examination or multidisciplinary assessment.

North America generally benefits from established rheumatology networks and advanced imaging, although affordability and access remain important barriers. Europe has strong guideline infrastructure but substantial variation in referral timing, reimbursement, and biologic access across countries. Asia-Pacific combines sophisticated specialist services in some settings with significant unmet diagnostic needs in others. Latin America faces uneven access to rheumatologists, imaging, and advanced therapies. In the Middle East, specialized centers coexist with fragmented access and variable recognition. Africa experiences particularly pronounced constraints in diagnostic capacity, specialist availability, and continuity of care, highlighting the importance of adaptable referral and education models.

Within ASEAN, BRICS, the European Union, G7, GCC, and NATO groupings, AS management differs according to health-system resources, insurance structures, clinical workforce, and procurement arrangements. The European Union benefits from shared scientific and regulatory collaboration, while the G7 generally has strong specialist and research capacity but still faces inequities in access. ASEAN and BRICS contain wide internal variation in diagnostics and treatment availability. GCC systems often include well-resourced urban centers, whereas broader NATO and member-state comparisons underscore differences in public coverage, military and veteran health services, and cross-border clinical standards.

Australia, Canada, France, Germany, Italy, Japan, South Korea, Spain, the United Kingdom, and the United States have established rheumatology services, but referral pathways, imaging access, reimbursement, and treatment monitoring differ. China and India combine expanding specialist capacity with substantial regional variation and large populations requiring scalable education and referral systems. Brazil and Mexico face disparities between major urban centers and underserved areas. Russia’s care environment is shaped by geographic scale and access variation. Across all listed countries, priorities include reducing diagnostic delay, improving recognition of extra-articular disease, coordinating primary and specialist care, and supporting adherence to exercise and treatment plans.

Leaders should invest in clinician education that distinguishes inflammatory from mechanical back pain, strengthen referral pathways from primary care, and support validated imaging and outcome-assessment protocols. Patient services should reinforce exercise, smoking cessation, medication adherence, vaccination discussions, and monitoring for eye, skin, bowel, and cardiovascular manifestations. Digital and AI initiatives should use transparent validation, privacy protections, human review, and inclusive datasets. Access strategies should account for local affordability, specialist scarcity, rural delivery, and continuity of care rather than focusing solely on treatment availability.

This executive summary uses a structured synthesis of established clinical knowledge concerning AS, including disease presentation, diagnostic practice, imaging, multidisciplinary management, treatment monitoring, regional health-system conditions, and responsible digital-health adoption. Findings are framed qualitatively and avoid market estimates, market shares, forecasts, and company-specific claims. Regional, group, and country observations are presented as contextual comparisons rather than rankings, with emphasis on documented variation in healthcare capacity, access, and clinical pathways.

The principal opportunity in AS care is to shorten the path from symptom onset to accurate diagnosis and sustained, function-preserving management. Better coordination among primary care, rheumatology, radiology, physiotherapy, ophthalmology, dermatology, gastroenterology, and patients can improve continuity and address disease beyond the spine. Responsible use of AI may strengthen this model, but equitable access, clinical accountability, and evidence-based decision-making must remain central.